Step by Step Guide To More Income!
Whether you are just starting to trade or believe you’re never too old to learn new tricks, "How To Master the Retirement Trade" is for you!

From options expert Dave Aquino, this e-book will guide you through the morning trade window bringing profits to newbies and seasoned pros alike.
Get yours now!
Paul Sauer, insider at Vaxcyte
Paul Sauer Insider Alerts

Get notified the next time Paul Sauer buys or sells Vaxcyte stock. Enter your email address below to get our daily insider buying and selling report.

Paul Sauer Insider Information

SVP of Vaxcyte
Paul has over 30 years of experience industrializing biologics for numerous biotechnology companies. Prior to joining Vaxcyte, Paul was VP of Process Sciences & Manufacturing at Igenica Biotherapeutics, where he initiated the company’s development activities and built its supply chain network for GMP manufacturing of its antibody drug conjugates. Prior to that, Paul was Senior Director of Process Development at OncoMed Pharmaceuticals, where he contributed to multiple IND filings for the company’s antibody-based oncology therapies. He also held various process, engineering, scale-up, and manufacturing positions at Protein Design Labs, Scios, and Genentech. Through the years, Paul has contributed to numerous approved biologics, including Genentech’s Activase® and Pulmozyme®. He also contributed significantly to the development of the patented high-yield process that formed the basis for production of Abbvie and Biogen’s ZinbrytaTM, a humanized antibody approved for the treatment of Multiple Sclerosis. Paul earned an MBA at Santa Clara University and a BS in Genetics from the University of California, Davis. Paul enjoys spending quality time with his family and helping his wife with her non-profit organization focused on transforming health through diet.

What is Paul Sauer's net worth?

The estimated net worth of Paul Sauer is at least $1.42 million as of February 11th, 2021. Mr. Sauer owns 80,399 shares of Vaxcyte stock worth more than $1,417,434 as of January 20th. This net worth evaluation does not reflect any other assets that Mr. Sauer may own. Learn More.

How old is Paul Sauer?

Mr. Sauer is currently 59 years old. There are 6 older executives and no younger executives at Vaxcyte. Learn More.

How do I contact Paul Sauer?

The corporate mailing address for Mr. Sauer and other Vaxcyte executives is 353 HATCH DRIVE, FOSTER CITY CA, 94404. Vaxcyte can also be reached via phone at 650-837-0111.

Has Paul Sauer been buying or selling shares of Vaxcyte?

Paul Sauer has not been actively trading shares of Vaxcyte during the last quarter. Most recently, Paul Sauer sold 6,000 shares of the business's stock in a transaction on Wednesday, December 29th. The shares were sold at an average price of $25.00, for a transaction totalling $150,000.00.

Who are Vaxcyte's active insiders?

Vaxcyte's insider roster includes Jeff Fairman (VP), Andrew Guggenhime (CFO), Grant Pickering (CEO), Paul Sauer (SVP), and Jane Wright-Mitchell (General Counsel).

Are insiders buying or selling shares of Vaxcyte?

In the last year, insiders at the sold shares 36 times. They sold a total of 421,648 shares worth more than $10,503,183.57. The most recent insider tranaction occured on December, 29th when SVP Paul Sauer sold 6,000 shares worth more than $150,000.00. Insiders at Vaxcyte own 21.7 % of the company.

Information on this page was last updated on 12/29/2021.

Paul Sauer Insider Trading History at Vaxcyte

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/29/2021Sell6,000$25.00$150,000.00View SEC Filing Icon  
9/22/2021Sell5,307$25.20$133,736.40View SEC Filing Icon  
2/11/2021Sell2,500$26.65$66,625.0080,399View SEC Filing Icon  
1/11/2021Sell2,500$26.21$65,525.00View SEC Filing Icon  
See Full Table

Paul Sauer Buying and Selling Activity at Vaxcyte

This chart shows Paul Sauer's buying and selling at Vaxcyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vaxcyte Company Overview

Vaxcyte logo
Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in Foster City, California.
Read More

Today's Range

Now: $17.63
Low: $17.44
High: $18.75

50 Day Range

MA: $22.41
Low: $17.63
High: $26.45

2 Week Range

Now: $17.63
Low: $15.51
High: $29.29

Volume

407,763 shs

Average Volume

459,339 shs

Market Capitalization

$930.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56
5 Tech Stocks to Buy Immediately
Eric Fry, one of America's top Investment Strategists, provides his latest report 5 Top Stocks for 2022.

You can't afford to miss out on the once in a decade chance to buy after the recent dip in the markets.
Download this hot-off-the-presses research report now. It’s yours FREE.